

**Mycoprotein ingestion stimulates protein synthesis rates to a greater extent than milk protein in rested and exercised skeletal muscle of healthy young men: a randomised controlled trial.**

Alistair J Monteyne<sup>1</sup>, Mariana OC Coelho<sup>1</sup>, Craig Porter<sup>2</sup>, Doaa R Abdelrahman<sup>2</sup>, Thomas SO Jameson<sup>1</sup>, Sarah R Jackman<sup>1</sup>, Jamie R Blackwell<sup>1</sup>, Tim JA Finnigan<sup>3</sup>, Francis B Stephens<sup>1</sup>, Marlou L Dirks<sup>1</sup>, Benjamin T Wall<sup>1</sup>

*<sup>1</sup>Department of Sport and Health Sciences, College of Life and Environmental Sciences, Heavitree Road, University of Exeter, UK*

*<sup>2</sup>Department of Surgery, University of Texas Medical Branch & Shriners Hospital for Children, Galveston, Texas, USA*

*<sup>3</sup>Marlow Foods Ltd, Station Road, Stokesly, North Yorkshire, UK*

**Keywords:** Mycoprotein, amino acids, muscle protein synthesis, resistance exercise

Running title: Mycoprotein and muscle protein synthesis

**Wordcount:**

**ClinicalTrials.gov** (ID: 660065600)

**Corresponding author:**

Benjamin T. Wall, PhD

Department of Sport and Health Sciences

College of Life and Environmental Sciences

St Luke's Campus, Heavitree Road

University of Exeter

Exeter, EX1 2LU

UK

Tel: +44 (0)139 272 4774

Email: [b.t.wall@exeter.ac.uk](mailto:b.t.wall@exeter.ac.uk)

Data described in the manuscript, code book, and analytic code will be made available upon request pending approval by the corresponding author.

## 1 Abstract

2 **Background:** Mycoprotein is a fungal-derived sustainable protein-rich food source, and its  
3 ingestion results in systemic amino acid and leucine concentrations similar to that following  
4 milk protein ingestion.

5 **Objective:** We assessed the mixed skeletal muscle protein synthetic response to the ingestion  
6 of a single bolus of mycoprotein compared with a leucine matched bolus of milk protein, in  
7 rested and exercised muscle of resistance-trained young men.

8 **Design:** Twenty resistance-trained healthy young males (age:  $22\pm 1$  y, body mass:  $82\pm 2$  kg,  
9 BMI:  $25\pm 1$   $\text{kg}\cdot\text{m}^{-2}$ ) took part in a randomized, double-blind, parallel-group study. Participants  
10 received primed, continuous infusions of L-[ring- $^2\text{H}_5$ ]phenylalanine and ingested either 31 g  
11 (26.2 g protein: 2.5 g leucine) milk protein (MILK) or 70 g (31.5 g protein: 2.5 g leucine)  
12 mycoprotein (MYCO) following a bout of unilateral resistance-type exercise (contralateral  
13 leg acting as resting control). Blood and *m. vastus lateralis* muscle samples were collected  
14 before exercise and protein ingestion, and following a 4 h postprandial period to assess mixed  
15 muscle fractional protein synthetic rates (FSR) and myocellular signalling in response to the  
16 protein beverages in resting and exercised muscle.

17 **Results:** Mixed muscle FSR increased following MILK ingestion (from  $0.036\pm 0.008$  to  
18  $0.052\pm 0.006\% \cdot \text{h}^{-1}$  in rested, and  $0.035\pm 0.008$  to  $0.056\pm 0.005\% \cdot \text{h}^{-1}$  in exercised muscle;  
19  $P<0.01$ ) but to a greater extent following MYCO ingestion (from  $0.025\pm 0.006$  to  
20  $0.057\pm 0.004\% \cdot \text{h}^{-1}$  in rested, and  $0.024\pm 0.007$  to  $0.072\pm 0.005\% \cdot \text{h}^{-1}$  in exercised muscle;  
21  $P<0.0001$ ) (treatment  $\times$  time interaction effect;  $P<0.05$ ). Postprandial FSRs trended to be  
22 greater in MYCO compared with MILK ( $0.065\pm 0.004$  vs  $0.054\pm 0.004\% \cdot \text{h}^{-1}$ , respectively;  
23  $P=0.093$ ) and the postprandial rise in FSR was greater in MYCO compared with MILK ( $\Delta$   
24  $0.040\pm 0.006$  vs  $\Delta 0.018\pm 0.005\% \cdot \text{h}^{-1}$ , respectively;  $P<0.01$ ).

25 **Conclusions:** The ingestion of a single bolus of mycoprotein stimulates resting and post-  
26 exercise muscle protein synthesis rates, and to a greater extent compared with a leucine  
27 matched bolus of milk protein, in resistance-trained young men.

28

## 29 **Introduction**

30 Adequate dietary protein intake is required to maintain skeletal muscle mass and to facilitate  
31 the remodelling and/or hypertrophy of muscle tissue in response to exercise training.

32 Mechanistically, this is largely achieved by dietary protein ingestion transiently (2-5 h)  
33 stimulating muscle protein synthesis rates (1-3), primarily due to a postprandial elevation of  
34 plasma essential amino acid concentrations (4), particularly leucine (5, 6). A single bout of  
35 resistance exercise also stimulates muscle protein synthesis rates for up to (and at least) 48 h  
36 (7, 8), whilst sensitising muscle tissue to the anabolic effects of dietary protein for at least 24  
37 h (7, 8). Consequently, research has sought to identify aspects of protein nutrition (e.g.  
38 amount and timing) that can be manipulated to optimally support post-exercise muscle  
39 protein synthesis rates (1, 3, 9-12). However, information relating to the anabolic properties  
40 of non-animal derived dietary protein sources is lacking, which is concerning given the  
41 increasing emphasis on dietary sustainability.

42 Animal-derived dietary protein sources, such as whey (1, 2, 11, 13, 14), casein (13, 15), milk  
43 (16, 17) beef (17-20) and egg (3, 21) have all been shown to stimulate post-exercise muscle  
44 protein synthesis rates. It is assumed that plant-based dietary protein sources are inferior in  
45 their capacity to stimulate muscle protein synthesis rates, due to their typically slower  
46 digestibility, lower bioavailability, and lower essential amino acid and leucine content (22).  
47 Indeed, whey protein stimulates muscle protein synthesis rates to a greater extent than soy in  
48 young men (1, 14) and, compared to wheat protein in older men (13). To date, however, these  
49 are the only non-animal derived protein sources to be studied with respect to their impact on  
50 muscle protein synthesis.

51 Mycoprotein is a sustainably produced food source rich in protein (~45% of total mass) and  
52 essential amino acids (~44% of total protein) derived from the cultivation of the fungus  
53 *Fusarium venenatum*. We have reported that total postprandial essential amino acid (and

54 leucine) concentrations following mycoprotein ingestion are comparable to that seen  
55 following milk protein ingestion (23), a finding atypical of animal versus non-animal dietary  
56 protein comparisons (13, 24). Further, essential amino acid concentrations following  
57 mycoprotein ingestion increased in a dose-response fashion up to 60-80 g mycoprotein  
58 consumption (27-36 g protein, 2.1-2.9 g leucine) (23), suggesting mycoprotein would be  
59 capable of robustly stimulating muscle protein synthesis rates.

60 In the present work, we tested the hypothesis that the ingestion of a 70 g bolus of  
61 mycoprotein (31.5 g protein, 2.5 g leucine) would stimulate mixed muscle protein synthesis  
62 rates over a four h postprandial period in both rested and exercised skeletal muscle of  
63 resistance-trained, healthy young men. We compared the muscle protein synthetic response  
64 of mycoprotein ingestion to a leucine-matched bolus of milk protein. Here, we hypothesised  
65 that, despite equivalent leucine contents, due to slower aminoacidemia (23), muscle protein  
66 synthesis rates would increase to a lesser extent following mycoprotein ingestion. We chose  
67 to match the two beverages on leucine content as various lines of enquiry suggest leucine  
68 content, rather than total protein, is the primary factor determining the postprandial muscle  
69 protein synthetic response when sufficient protein is consumed (6, 25, 26).

70

## 71 **Methods**

### 72 *Participants*

73 Twenty young, healthy (age:  $22\pm 1$  y, body mass:  $82\pm 2$  kg, BMI:  $25\pm 1$  kg·m<sup>-2</sup>) men  
74 volunteered to take part in the present study (**Supplementary Figure 1**). Participants'  
75 characteristics are displayed in **Table 1**. Participants were recreationally active and  
76 experienced with resistance training (at least 3 times per week for at least 3 months prior to  
77 participation). Participants were deemed healthy based on their blood pressure  
78 ( $\leq 140/90$  mmHg), BMI ( $18$ - $30$  kg·m<sup>-2</sup>) and responses to a routine medical screening  
79 questionnaire (absence of any diagnosed metabolic impairment, cardiovascular disease, or  
80 motor disorders), and were informed of the experimental procedures, potential risks, and the  
81 purpose of the study prior to providing full written consent. Participants were all 'tracer  
82 naïve' having not undergone any previous stable isotope amino acid infusion protocols. The  
83 study was approved by the Sport and Health Sciences ethics committee of the University of  
84 Exeter (REF NO. 161026/B/05) in accordance with standards for human research as outlined  
85 in the declaration of Helsinki. Recruitment and data collection were completed between  
86 January 2017 and August 2017 at The University of Exeter.

87

### 88 *Pre-testing*

89 Following screening and acceptance onto the study, all participants underwent a single pre-  
90 testing session, which took place at least 5 days prior to the experimental trial. Participants  
91 were familiarised with the exercise equipment and exercise protocol, and body fat and lean  
92 mass were determined by Air Displacement Plethysmography (BodPod, Life Measurement,  
93 Inc. Concord, CA, USA). Participants were familiarised with the unilateral resistance-type  
94 exercise that was employed in the experimental protocol. This consisted of 5 sets of 30  
95 repetitions of maximal concentric isokinetic leg extension and leg flexion contractions on a

96 Biodex System 3 isokinetic dynamometer (Biodex Medical Systems, Shirley, NY, USA) at a  
97 speed of 60° per second over a central 80° range of motion using their self-reported dominant  
98 leg. Verbal encouragement was provided throughout the familiarisation and experimental  
99 testing to engender maximal effort through every repetition. Work done (J) was recorded for  
100 each completed set, and fatigue was calculated as the percentage decrement in work done  
101 between the first and last set. Participants were instructed to report their habitual dietary  
102 intake by recording a weighted food diary for two weekdays, and one weekend day prior to  
103 partaking in the study (Table 1) (Nutritics LTD, Dublin, Ireland).

104

#### 105 *Experimental protocol*

106 Participants were randomly assigned to two parallel-groups, A or B, by the lead investigator  
107 and completed a single trial in a double-blind fashion. An overview of the experimental  
108 protocol is shown in **Figure 1**. Participants were directed to abstain from vigorous physical  
109 activity and alcohol consumption in the 48 h preceding the trial. All participants were  
110 provided with and consumed a standardised meal ~10.5 h prior to the start of the  
111 experimental trial (744 kcal [3.1 MJ], 29% energy (%En) fat, 20%En protein, 51%En  
112 carbohydrate). On the day of the trial, participants arrived at the laboratory between 07:00 -  
113 08:00 after a 10 h overnight fast. A Teflon™ cannula was inserted into an antecubital vein of  
114 one arm in preparation for stable isotope infusion, a baseline venous blood sample was taken  
115 from this site to measure background isotope enrichments prior to infusion. Following  
116 baseline blood sampling (t = -210 min) the phenylalanine and tyrosine pools were primed  
117 with a single intravenous dose of L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine (2.12 μmol/kg) and L-[3,3-  
118 <sup>2</sup>H<sub>2</sub>]tyrosine (0.75 μmol/kg). Thereafter, continuous tracer infusion was initiated and  
119 maintained at a rate of 0.035 μmol·kg<sup>-1</sup>·min<sup>-1</sup> for L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine and 0.012  
120 μmol·kg<sup>-1</sup>·min<sup>-1</sup> for L-[3,3-<sup>2</sup>H<sub>2</sub>]tyrosine for the duration of the protocol. Once the infusion

121 had begun, a second Teflon cannula was inserted into a dorsal hand vein of the contralateral  
122 arm and placed in a warmed air hand unit (55°C) for arterialized venous blood sampling (27).  
123 Arterialized venous blood samples were collected throughout the experimental protocol at the  
124 following time points:  $t = -180, -120, -60, 0$  (drink consumption), 15, 30, 45, 60, 75, 90, 120,  
125 150, 180, 210 and 240 min. A baseline muscle sample was collected after 90 min of the  
126 infusion ( $t = -120$  min) from the non-dominant leg (designated as the 'resting leg'). Muscle  
127 biopsies were collected from the mid-region of the *m. vastus lateralis* (approx. 15 cm above  
128 the patella) with a modified Bergström suction needle under local anaesthesia (2% lidocaine).  
129 All biopsy samples were immediately freed from any visible blood, adipose and connective  
130 tissue, frozen in liquid nitrogen (within 30 s), and stored at  $-80^{\circ}\text{C}$  until subsequent analysis.  
131 Eighty-five min after the initial biopsy ( $t = -35$  min), participants undertook the unilateral  
132 resistance-type exercise protocol, as previously described, which took 30 min. Immediately  
133 following exercise bilateral muscle biopsies were collected (i.e. from both the rested and  
134 exercised leg). Immediately post-biopsy ( $t = 0$  min) participants consumed either a milk  
135 protein (MILK) or mycoprotein (MYCO) beverage, within an allotted 5 min period, with the  
136 experimental drinks administered in a double-blind manner. Thereafter, participants rested in  
137 a semi-supine position for 4 h, after which further bilateral biopsies were collected 1–2 cm  
138 proximal to the previous incisions ( $t = 240$  min).

139

#### 140 *Experimental beverage preparations*

141 Freeze-dried isolated milk protein concentrate was obtained from a commercial supplier  
142 (Bulk Powders, Colchester, UK) and freeze-dried mycoprotein was produced by and obtained  
143 from Marlow Foods Ltd, Quorn Foods, Stokesley, UK. Both protein sources were  
144 independently analysed by a third party company for energy, macronutrient content and  
145 amino acid composition (Premier Analytical Services, High Wycombe, UK). The powdered

146 protein sources were prepared the evening before the experimental trial. The protein sources  
147 were assimilated with 400 mL water and 10 g of artificial energy-free flavouring (Myprotein,  
148 Manchester, UK), blended for approximately 2 min, topped up with water to make a total  
149 final beverage volume of 600 mL and refrigerated overnight. Drinks were enriched (2.5%)  
150 with L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine to account for postprandial tracer dilution by non-labelled  
151 phenylalanine and to maintain a systemic isotopic steady-state following protein ingestion (1,  
152 3). Following drink consumption by the participant, an additional 50 mL of water was then  
153 added to ‘wash’ the bottle and ensure that all protein had been consumed, making a total  
154 volume of 650 mL consumed by participants. All drinks were well tolerated, consumed  
155 within the allotted time (i.e. 5 min) and resulted in no adverse effects during or after the test  
156 day. Double blinding of the drinks was achieved by having a different researcher from the  
157 individual running the infusion trial prepare the drinks in an opaque bottle ready for  
158 consumption. Despite careful blinding, we cannot discount the possibility that participants  
159 allocated to MYCO may have perceived the unusual texture of mycoprotein. The milk protein  
160 beverage contained 31 g of milk protein powder which contained 26.2 g total protein  
161 (providing 2.5 g of leucine). The mycoprotein beverage contained 70 g of mycoprotein which  
162 contained 31.5 g total protein (providing 2.5 g of leucine). The detailed nutritional content  
163 and amino acid composition of the drinks are displayed in **Table 2**.

164

#### 165 *Blood sample collection and analyses*

166 Ten mL of arterialised venous blood was collected into a syringe at each sampling point. For  
167 each blood sample, six mL was aliquoted into liquid heparin containing tubes (BD vacutainer  
168 LH; Becton, Dickinson and Company, Franklin Lakes, NJ, USA) and centrifuged  
169 immediately (3000 g, 4°C, 10 min). Blood plasma was aliquoted and frozen at –80°C for  
170 subsequent analysis. The remaining 4 mL of blood was aliquoted into additional vacutainers

171 (BD vacutainers SST II, Becton, Dickinson and Company) which were left to clot at room  
172 temperature for at least 30 min and then centrifuged (3000 g, 4°C, 10 min) to obtain blood  
173 serum. Serum was aliquoted before freezing at -80°C for subsequent analyses. Serum insulin  
174 concentrations were analysed using a commercially available kit (DRG Insulin ELISA, EIA-  
175 2935, DRG International Inc, Springfield, IL, USA). Plasma branched chain amino acid  
176 (BCAA) (leucine, isoleucine and valine), phenylalanine and tyrosine concentrations, and L-  
177 [ring-<sup>2</sup>H<sub>5</sub>]-phenylalanine, L-[ring-3,5-<sup>2</sup>H<sub>2</sub>]-tyrosine, and L-[ring-<sup>2</sup>H<sub>4</sub>]-tyrosine enrichments  
178 were determined by gas chromatography-mass spectrometry (GC-MS) as described  
179 previously (28). Briefly, 10 µL internal standards of leucine, valine, phenylalanine and  
180 tyrosine were added to the samples. The plasma was deproteinised on ice with 500 µL of  
181 15% 5-sulfosalicylic acid. Free amino acids were purified using acid-washed cation exchange  
182 columns (AG 50W-X8 resin; Bio-Rad Laboratories, Inc., CA, USA), with the amino acids  
183 being eluted from the column with 8 mL of 2N ammonium hydroxide. The eluate was then  
184 dried under vacuum with a Speed-Vac rotary dryer (Savant Instruments, Farmingdale, NY,  
185 USA). In order to derivatize the plasma sample, 40 µl MTBSTFA + 1% tert-butyl-  
186 dimethylchlorosilane and 40 µl acetonitrile were added to the dry samples, vortexed and  
187 heated at 95 °C for 40 min (29). The samples were analyzed by GC-MS (7890 GC coupled  
188 with a 5975 inert MSD; Agilent Technologies, Santa Clara, CA, USA) in duplicates using  
189 electron impact ionization and selected ion monitoring for measurement of isotope ratios  
190 (30). One microliter of the sample was injected in splitless mode (injector temp. 280°C).  
191 Peaks were resolved using an HP5-MS 30m × 0.25mm ID × 0.25µm capillary column  
192 (Agilent). Helium was used as carrier gas at 1.2ml/min constant flow rate. The temperature  
193 ramp was set from 80 – 245 °C at 11°C/min, then to 280 °C at 40 °C/min (30). Selected ion  
194 recording conditions were used to monitor fragments m/z 336, 341 and 346 for

195 phenylalanine, m/z 288 and 296 for valine, m/z 274 and 280 for leucine and isoleucine, and  
196 m/z 466 and 475 for tyrosine.

197

### 198 *Skeletal muscle tissue analyses*

199 Muscle biopsy tissue samples were analysed for protein-bound and free intracellular L-[ring-  
200 <sup>2</sup>H<sub>5</sub>]phenylalanine, as previously described (28). Briefly, 20-30 mg of frozen muscle tissue  
201 was weighed and precipitated in 600 µL 10% perchloric acid. The tissue was homogenized  
202 by a mechanical tissue grinder. The supernatant, for determination of intracellular L-[ring-  
203 <sup>2</sup>H<sub>5</sub>]phenylalanine enrichment, was subsequently transferred following centrifugation (4000  
204 rpm, 20 min, 4 °C) and stored at -80 °C. This procedure was repeated with an additional 800  
205 µL wash with 10% perchloric acid. The remaining pellet of muscle tissue was washed three  
206 times in 2% perchloric acid, twice in ethanol, and then once in ethyl ether, before being oven-  
207 dried overnight at 50 °C. The following day, the dried muscle pellet was hydrolysed in 6N  
208 hydrochloric acid at 110 °C for 24 h. The hydrolysate, representing the bound protein pool of  
209 amino acids, was subsequently used to determine the enrichment of bound L-[ring-  
210 <sup>2</sup>H<sub>5</sub>]phenylalanine. The protein hydrolysate was deionized using ion-exchange columns as  
211 described for blood analyses. The supernatant, for determination of intracellular labelled  
212 phenylalanine enrichment, was prepared in the same manner as the protein-bound acid  
213 hydrolysates. In order to derivatize the muscle sample, 50 µl MTBSTFA + 1% tert-butyl-  
214 dimethylchlorosilane and 50 µl acetonitrile were added to the dry samples, vortex mixed and  
215 heated at 95 °C for 45 min (29). The samples were analyzed by GC-MS (7890 GC coupled  
216 with a 5975 inert MSD; Agilent Technologies) in duplicates using electron impact ionization  
217 and selected ion monitoring for measurement of isotope ratios (30). One microliter of the  
218 sample was injected in splitless mode (injector temp. 280 °C). Peaks were resolved using an  
219 HP5-MS 30m × 0.25mm ID × 0.25µm capillary column (Agilent). Helium was used as

220 carrier gas at 1.2ml/min constant flow rate. The temperature ramp was set from 80 – 245 °C  
221 at 11 °C/min, then to 280 °C at 40 °C/min (30). Selected ion recording conditions were used  
222 to monitor fragments m/z 237 and 239 for the m+3 and m+5 fragments of phenylalanine  
223 bound protein and m/z 336 and 341 for phenylalanine free fraction.

224 Muscle biopsy tissue samples were analysed for total and phosphorylated forms of  
225 mechanistic target of rapamycin (mTORSer<sup>2448</sup> and pmTOR Ser<sup>2448</sup>). Briefly, ~10 mg of  
226 whole frozen muscle was mechanically homogenised using steel beads (Qiagen, Hilden,  
227 Germany) in 20 volumes of buffer (Tris-HCl 50 mM, Triton X-100 1%, EDTA 1 mM, EGTA  
228 1 mM, NaF 50 mM, β-glycerophosphate 10 mM, sodium pyrophosphate 5 mM, 2-  
229 mercaptoethanol 0.1%, sodium orthovanadate 0.5 mM, okadaic acid 100 nM and complete  
230 Mini protease inhibitor cocktail (Roche Holding AG, Basel, Switzerland). Following  
231 centrifugation (10000 g, 4°C, 10 min) the supernatant protein content was determined by  
232 colorimetric assay (DC protein assay, Bio-Rad Laboratories, Inc.). Proteins were unfolded by  
233 incubating for 5 minutes at 95 °C in XT sample buffer (Bio-Rad Laboratories, Inc.). Twenty  
234 µg protein per lane were loaded onto 3-8% tris acetate polyacrylamide gels, and separated by  
235 electrophoresis in XT tricine running buffer for 65 min at 150 V. Proteins were transferred to  
236 0.2 µM nitrocellulose membranes using a Trans-blot turbo transfer system (Bio-Rad  
237 Laboratories, Inc.), at 2.5 A and 25 V for 10 min. Membranes were blocked in 5% BSA in  
238 TBST (pH 7.6) for 1 h, before overnight incubation at 4 °C with rabbit anti-phospho-mTOR  
239 Ser<sup>2448</sup> monoclonal antibody (5536, Cell Signaling Technology, Inc., Danvers, Mass, USA;  
240 1:1000 in TBST) and rabbit anti-α-tubulin (11H10, Cell Signaling Technology, Inc.; 1:20000  
241 in TBST) loading control. Following 3 × 10 min washes in TBST, membranes were  
242 incubated for 1 h at room temperature in secondary HRP conjugated anti-rabbit IgG antibody  
243 (ab6721, Abcam PLC, Cambridge, UK; 1:3000 in TBST). Following 3 × 10 min washes in  
244 TBST, membranes were then exposed for 5 min in Clarity Western chemiluminescent

245 detector solution (Bio-Rad Laboratories, Inc.), visualised using a Chemidoc scanner (Bio-Rad  
246 Laboratories, Inc.), and band density quantified using Image Lab software (Bio-Rad  
247 Laboratories, Inc.). The expected migration of phospho-mTOR (~289 kDa) and  $\alpha$ -tubulin  
248 (~52 kDa) was confirmed using a kaleidoscope protein ladder (Bio-Rad Laboratories, Inc.).  
249 For total mTOR, membranes were incubated for 15 min in Restore stripping buffer (Thermo  
250 Fisher Scientific, Waltham, MA, USA), blocked for 1 h in 5 % BSA in TBST and re-probed  
251 overnight with an anti-mTOR monoclonal primary antibody (2972, Cell Signaling  
252 Technology, Inc.; 1:1000 in TBST) plus anti- $\alpha$ -tubulin, and the above steps were repeated to  
253 obtain corresponding bands for total mTOR. The band density for phospho-mTOR was  
254 calculated as a ratio against the band density for  $\alpha$ -tubulin, within each lane. This was divided  
255 by the ratio of mTOR against  $\alpha$ -tubulin to give an overall ratio for 'mTOR phosphorylation  
256 status', which was finally expressed as a fold change from the rested, fasted, baseline.  
257 Skeletal muscle mRNA expression of 48 genes was analysed as previously described (31). In  
258 brief, total RNA was extracted from ~20 mg frozen muscle tissue using TRIzol<sup>®</sup> Reagent  
259 (Thermo Fisher Scientific) (32), according to the manufacturer's protocol. Total RNA  
260 quantification was carried out spectrophotometrically at 260 nm (NanoDrop ND-2000  
261 Spectrophotometer; Thermo Fisher Scientific) and RNA purity was determined as the ratio of  
262 readings at 260/280 nm. Reverse transcription of RNA was carried out using a commercially  
263 available kit (SuperScript<sup>™</sup> III First-Strand Synthesis SuperMix, Thermo Fischer Scientific)  
264 (33). Taqman low-density custom-designed array cards (Thermo Fisher Scientific) were used  
265 for the relative quantification of the expression of genes involved in the regulation of cellular  
266 amino acid transport, protein synthesis and protein breakdown. Each card allowed for eight  
267 samples to be run in parallel against 48 Taqman gene expression assay targets that had been  
268 preloaded into each well on the card (**Table 4**). In short, 50  $\mu$ L Taqman Universal Master  
269 Mix II (Thermo Fisher Scientific) was added to 150 ng of RNA equivalent cDNA into an

270 RNase-free Eppendorf tube, and RNase-free water was added to make the total reaction  
 271 volume up to 100  $\mu$ l. The reaction mixture was vortexed, centrifuged and loaded into one of  
 272 the fill reservoirs of the Micro Fluidic card, after which the cards were centrifuged (Hereaus 3  
 273 S-RMicrofuge, Thermo Fisher Scientific) and run on a 7900HT Fast Real-Time PCR System  
 274 (Thermo Fisher Scientific). Relative quantification of the genes of interest was performed  
 275 using the delta-delta Ct method, with the fold change in mRNA amplification expressed  
 276 relative to the rested fasted leg and the geometric mean of the two housekeeping genes, for  
 277 which purpose GAPDH and B2M were selected.

278

### 279 *Calculations*

280 The fractional synthetic rates (FSR) of mixed muscle proteins were calculated using the  
 281 standard precursor-product equation (28):

$$282 \quad FSR (\% \cdot h^{-1}) = \left[ \frac{\Delta E_p}{E_{\text{precursor}} \times t} \right] \times 100$$

283 Where  $\Delta E_p$  is the increment in L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine enrichment in mixed muscle  
 284 protein between two biopsies,  $E_{\text{precursor}}$  is the average L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine enrichment  
 285 in the plasma or intracellular precursor pool over time, and  $t$  indicates the tracer incorporation  
 286 time (h) between two muscle biopsies.

287

288 Intravenous infusion of L-[ring-<sup>2</sup>H<sub>5</sub>]-phenylalanine and L-[ring-3,5-<sup>2</sup>H<sub>2</sub>]-tyrosine and  
 289 arterialized venous blood sampling were used to assess whole-body amino acid kinetics under  
 290 non-steady state conditions (34). Whole-body total phenylalanine rates of appearance ( $R_a$ ),  
 291 rates of disappearance ( $R_d$ ), and hydroxylation rates (the initial step in phenylalanine  
 292 oxidation) were calculated using modified Steele's equations (34), as follows:

$$293 \quad Total R_a = \frac{F_{iv} - \left[ pV \times C(t) \times \frac{dE_{iv}}{dt} \right]}{E_{iv}(t)}$$

$$294 \quad Total R_d = R_a - pV \times \frac{dc}{dt}$$

$$295 \quad Phe \text{ Hydroxylation} = Tyr R_a \times \frac{E_{tyr}(t)}{E_{phe}(t)} \times \frac{Phe R_d}{F_{phe} + Phe R_d}$$

296 Where  $F_{iv}$  is the intravenous tracer infusion rate ( $\mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ ),  $pV$  ( $0.125 \text{ L}\cdot\text{kg}^{-1}$ ) is the  
 297 distribution volume for phenylalanine (34),  $C(t)$  is the mean plasma phenylalanine  
 298 concentration between two consecutive time points,  $dE_{iv}/dt$  represents the time-dependent  
 299 variations of plasma phenylalanine enrichments derived from the intravenous tracer, and  
 300  $E_{iv}(t)$  is the mean plasma phenylalanine enrichment from the intravenous tracer between two  
 301 consecutive time points.  $Tyr R_a$  is the total rate of appearance based on the L-[ring-3,5- $^2\text{H}_2$ ]-  
 302 tyrosine infusion and plasma enrichment of tyrosine.  $E_{tyr}(t)$  and  $E_{phe}(t)$  are the mean plasma  
 303 L-[ring- $^2\text{H}_4$ ]-tyrosine and L-[ring- $^2\text{H}_5$ ]-phenylalanine enrichments between 2 consecutive  
 304 time points, respectively, and  $F_{phe}$  is the intravenous infusion rate of L-[ring- $^2\text{H}_5$ ]-  
 305 phenylalanine ( $\mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ ).

306 The absence of an additional (unique) tracer within the protein drinks precluded us being able  
 307 to differentiate between endogenous and exogenous  $R_a$ . Furthermore, the necessity to enrich  
 308 the experimental drinks with the same tracer as was intravenously infused, to minimize  
 309 disturbance in precursor isotopic steady states, precluded the calculation of whole body  
 310 protein synthesis and breakdown, and provides a degree of error which we presume to be  
 311 equivalent across the two groups.

312

313 *Statistical analyses*

314 A two-sided power analysis based on previous research (1) showed that  $n=9$  per condition was  
315 sufficient to detect expected differences in postprandial muscle protein synthesis rates between  
316 protein conditions (MILK vs MYCO) when using a repeated measures ANOVA ( $P < 0.05$ ,  
317 90% power,  $f = 0.67$ ; G\*power version 3.1.9.2). Our primary measure was postprandial muscle  
318 protein synthesis rates. The delta change in muscle protein synthesis rates from fasted to fed,  
319 plasma amino acid concentrations (including  $C_{\max}$  and  $t_{\max}$ ), serum insulin concentrations,  
320 whole body amino acid kinetics, intracellular and mixed muscle protein-bound L-[ring-  
321  $^2\text{H}_5$ ]phenylalanine represent secondary measures, and skeletal muscle cell signalling responses  
322 represent exploratory variables. Differences in participant characteristics and background  
323 mixed muscle protein-bound L-[ring- $^2\text{H}_5$ ]phenylalanine were analysed using independent t-  
324 tests. Plasma amino acid and serum insulin concentrations, plasma L-[ring- $^2\text{H}_5$ ]-phenylalanine,  
325 L-[ring-3,5- $^2\text{H}_2$ ]-tyrosine, and L-[ring- $^2\text{H}_4$ ]-tyrosine enrichments, and muscle mTOR  
326 phosphorylation were tested by two-factor (treatment [milk protein vs mycoprotein]  $\times$  time)  
327 repeated-measures analysis of variance (ANOVA). Mixed muscle FSRs, mixed muscle  
328 protein-bound L-[ring- $^2\text{H}_5$ ]phenylalanine enrichments, and muscle gene expression were  
329 analysed using a three-factor (treatment  $\times$  time  $\times$  exercise/rest) ANOVA. Data were tested for  
330 sphericity, and where violations occurred the Greenhouse-Geisser correction was automatically  
331 applied. Violations of normality were tested for using the Shapiro-Wilk test, and no  
332 considerable violations were found. When significant interaction effects were observed Sidak  
333 post hoc tests were performed to correct for multiple comparisons and locate individual  
334 differences. Total postprandial amino acid concentrations were calculated as incremental area  
335 under curve (iAUC), with baseline set as  $t = 0$ , and analysed using independent t-tests.  
336 Individual  $C_{\max}$  (peak concentration) and  $t_{\max}$  (time to peak concentration) were analysed using  
337 independent t-tests. Where plasma time point data were absent, missing data analyses was  
338 performed using regression imputation. Statistical significance was set at  $P < 0.05$ . Calculations

339 were performed using GraphPad Prism version 7.1 (GraphPad Software, San Diego, CA,  
340 USA). All data are expressed as mean  $\pm$  SEM.

341

## 342 **Results**

343

### 344 *Participant characteristics*

345 No differences in age, weight, height, BMI, body composition, or habitual nutritional intake  
346 were detected between groups (all  $P>0.05$ ; **Table 1**). No differences in total work performed  
347 during the experimental resistance exercise bout ( $29540\pm1782$  J in MILK vs  $30722\pm2059$  J in  
348 MYCO;  $P>0.05$ ) or in fatigue ( $19\pm3\%$  in MILK vs  $26\pm4\%$  in MYCO;  $P>0.05$ ) were detected  
349 between groups.

350

### 351 *Plasma amino acid and serum insulin concentrations*

352 Plasma total and individual BCAA concentrations during the experimental period are shown  
353 in **Figure 2**. Plasma total BCAA concentrations and each of the individual BCAAs all  
354 showed similar kinetic responses. Specifically, from similar fasting values across conditions,  
355 all parameters increased with protein ingestion (time effect;  $P<0.0001$ ) but to differing  
356 degrees between conditions (treatment  $\times$  time interaction effect;  $P<0.0001$ ). Plasma BCAA  
357 concentrations (**A**) peaked more rapidly and to a greater peak magnitude following the  
358 ingestion of MILK compared with MYCO. Plasma BCAA  $C_{\max}$  was significantly greater in  
359 MILK compared with MYCO ( $791\pm51$  vs  $646\pm25.9$   $\mu\text{mol}\cdot\text{L}^{-1}$ ;  $P<0.05$ ), mean  $t_{\max}$  was  
360  $82.5\pm15$  min in MILK and  $103\pm10$  min in MYCO ( $P>0.05$ ), and modal  $t_{\max}$  was 90 min in  
361 MILK and 120 min in MYCO. Plasma leucine concentrations (**C** and **D**) were different  
362 between conditions (treatment effect;  $P<0.05$ ), and were greater at 15, 30, and 45 min in  
363 MILK compared with MYCO ( $P<0.01$ ). Plasma leucine concentrations peaked at 30 min in  
364 MILK at  $299\pm36$   $\mu\text{mol}\cdot\text{L}^{-1}$  and at 75 min in MYCO at  $243\pm11$   $\mu\text{mol}\cdot\text{L}^{-1}$ . Plasma leucine  $C_{\max}$   
365 was significantly greater in MILK compared with MYCO ( $340\pm27$  vs  $258\pm9$   $\mu\text{mol}\cdot\text{L}^{-1}$   
366  $^1P<0.01$ ), mean  $t_{\max}$  was  $80\pm16$  min in MILK and  $89\pm10$  min in MYCO ( $P>0.05$ ), and modal

367  $t_{\max}$  was 30 min in MILK and 75 min in MYCO. Total postprandial plasma leucine  
368 concentrations were  $19\pm 8\%$  greater in MILK compared with MYCO ( $24420\pm 2333$  in MILK  
369 vs  $20831\pm 1279$   $\mu\text{mol}\cdot\text{L}^{-1}\times 4\text{h}$  in MYCO;  $P>0.05$ ) (**D**), whereas isoleucine and valine  
370 postprandial concentrations did not differ between conditions ( $P>0.05$ ) (**F** & **H**). Plasma  
371 phenylalanine and tyrosine concentrations increased with protein ingestion (time effect;  
372  $P<0.0001$ ) but also to differing degrees between conditions (treatment  $\times$  time interaction  
373 effect;  $P<0.0001$ ). Plasma phenylalanine concentrations (**K** and **L**) were greater in MILK  
374 compared with MYCO at 15 and 30 min ( $P<0.01$ ). Plasma tyrosine concentrations (**I** and **J**)  
375 were different between conditions (treatment effect;  $P<0.001$ ), and were greater in MILK  
376 compared with MYCO from 15-120 min ( $P<0.05$ ).

377 Serum insulin concentrations during the experimental period are displayed in **Figure 3**. From  
378 similar fasting concentrations ( $15\pm 3$  and  $16\pm 2$   $\text{mU}\cdot\text{L}^{-1}$  in MILK and MYCO, respectively)  
379 serum insulin concentrations increased with protein ingestion (time effect;  $P<0.0001$ ) and to  
380 differing degrees between conditions (treatment  $\times$  time interaction effect;  $P<0.0001$ ). Milk  
381 protein ingestion resulted in a more rapid and transient increase in serum insulin  
382 concentrations that peaked at 15 min ( $42\pm 7$   $\text{mU}\cdot\text{L}^{-1}$ ) and returned to fasting levels by 45 min  
383 ( $P<0.01$ ). Mycoprotein ingestion induced a less rapid but more sustained increase in serum  
384 insulin concentrations that peaked at 30 min post-ingestion ( $36\pm 4$   $\text{mU}\cdot\text{L}^{-1}$ ) and returned to  
385 baseline more slowly (60 min;  $P<0.0001$ ). Serum insulin concentrations in MILK were only  
386 greater than MYCO at 15 min post-ingestion ( $P<0.05$ ) and postprandial serum insulin AUC  
387 was not different between conditions ( $P>0.05$ ). Serum insulin  $C_{\max}$  was not different between  
388 conditions ( $45\pm 6$  vs  $38\pm 3$   $\text{mU}\cdot\text{L}^{-1}$  in MILK and MYCO, respectively;  $P>0.05$ ), mean  $t_{\max}$  was  
389  $28\pm 5$  min in MILK and  $33\pm 4$  min in MYCO ( $P>0.05$ ), and modal  $t_{\max}$  was 15 min in MILK  
390 and 30 min in MYCO.

391

392 *Whole-body phenylalanine kinetics*

393 The time-course of plasma L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine, L-[3,3-<sup>2</sup>H<sub>2</sub>]tyrosine, and L-[ring-<sup>2</sup>H<sub>4</sub>]-  
394 tyrosine enrichments are illustrated in **Figure 4**. During the postabsorptive period, plasma L-  
395 [ring-<sup>2</sup>H<sub>5</sub>]phenylalanine remained in a steady state at ~4–5 MPE (mole percent excess) in  
396 both conditions. L-[ring-<sup>2</sup>H<sub>5</sub>] phenylalanine enrichments increased transiently after protein  
397 ingestion (time effect;  $P<0.001$ ), with a greater increase in MYCO (treatment  $\times$  time  
398 interaction effect,  $P<0.01$ ). Specifically, plasma L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine enrichments  
399 increased above postabsorptive levels for 30 min in MYCO only ( $P<0.01$ ) before returning to  
400 baseline enrichments. This was presumably due to either the slower digestion of MYCO, or  
401 quicker entry of labelled L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine into the circulation in the MYCO  
402 condition (Figure 4A). Two participants were excluded from the whole body kinetics analysis  
403 (final analysis therefore; MILK=9, MYCO=9) due to technical issues with the tyrosine tracer.  
404 L-[3,3-<sup>2</sup>H<sub>2</sub>]tyrosine decreased equivalently after the ingestion of protein (time effect;  
405  $P<0.0001$ , treatment  $\times$  time interaction effect;  $P>0.05$ ) and remained below postabsorptive  
406 levels for 150 min following protein ingestion ( $P<0.05$ ) (Figure 4B). Plasma L-[ring-<sup>2</sup>H<sub>4</sub>]-  
407 tyrosine increased following protein ingestion (time effect;  $P<0.0001$ ), with a greater increase  
408 in MYCO (treatment  $\times$  time interaction effect;  $P<0.01$ ) which was elevated above  
409 postabsorptive enrichments for 30 min ( $P<0.0001$ ) (Figure 4C). Phenylalanine hydroxylation  
410 increased following protein ingestion (time effect;  $P<0.0001$ ), and remained elevated  
411 throughout the postprandial period, with no differences between conditions (treatment  $\times$  time  
412 effects;  $P>0.05$ ) (Figure 5A). Plasma phenylalanine total  $R_a$  and  $R_d$  changed divergently over  
413 time in MILK and MYCO (time and treatment  $\times$  time effects;  $P>0.001$ ). In MILK  
414 phenylalanine total  $R_a$  and  $R_d$  were elevated above postabsorptive values at 90 min ( $P<0.05$ ),  
415 whereas in MYCO phenylalanine total  $R_a$  and  $R_d$  were suppressed below postabsorptive  
416 values at 30 min ( $P<0.01$ ) (Figure 5B-C).

417

418 *Skeletal muscle tracer analyses*

419 One participants' samples were excluded from the MYCO condition due to insufficient  
420 tissue. Intracellular L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine enrichments increased over time (time effect;  
421  $P<0.01$ ) with no differences between conditions or interaction effects (both  $P>0.05$ )  
422 (**Supplementary Figure 2**). Mixed muscle protein-bound L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine  
423 enrichments did not differ between conditions at baseline ( $0.0030\pm 0.0007$  and  $0.0034\pm 0.0006$   
424 MPE in MYCO and MILK conditions, respectively;  $P>0.05$ ). Mixed muscle protein L-[ring-  
425 <sup>2</sup>H<sub>5</sub>]phenylalanine enrichments increased during the fasting period in the rested leg (from  
426  $0.0030\pm 0.0007$  to  $0.0065\pm 0.0007$  in MILK and  $0.0034\pm 0.0006$  to  $0.0058\pm 0.0006$  MPE in  
427 MYCO; time effect;  $P<0.0001$ ) to the same extent in each condition (treatment and treatment  
428  $\times$  time effects; both  $P>0.05$ ). Mixed muscle protein L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine enrichments  
429 increased with protein ingestion (from  $0.0065\pm 0.0007$  to  $0.0161\pm 0.001$  MPE in rested, and  
430  $0.0061\pm 0.0008$  to  $0.0164\pm 0.0012$  MPE in exercised muscle in MILK, and from  
431  $0.0058\pm 0.0006$  to  $0.0167\pm 0.0012$  MPE in rested, and  $0.0055\pm 0.0006$  to  $0.0187\pm 0.0011$  MPE  
432 in exercised muscle in MYCO;  $P<0.0001$ ) and to a greater extent in MYCO compared with  
433 MILK (treatment  $\times$  time interaction effect;  $P<0.05$ ) (**Supplementary Figure 3**).

434 Mixed muscle FSRs calculated using the average plasma L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine plasma  
435 enrichment as the precursor pool are displayed in **Figure 6**. Exercise did not affect mixed  
436 muscle FSR (exercise effect;  $P=0.0640$ ), nor did exercise interact with protein ingestion  
437 ( $P=0.1251$ ) or condition ( $P=0.2223$ ). Protein ingestion increased mixed muscle FSRs in  
438 rested and exercised muscle in both conditions (time effect;  $P<0.0001$ ). Mixed muscle FSR  
439 increased from  $0.036\pm 0.008$  to  $0.052\pm 0.006\% \cdot h^{-1}$  and  $0.035\pm 0.008$  to  $0.056\pm 0.005\% \cdot h^{-1}$  in  
440 rested and exercised muscle, respectively, in MILK, and from  $0.025\pm 0.006$  to  
441  $0.057\pm 0.004\% \cdot h^{-1}$  and  $0.024\pm 0.007$  to  $0.072\pm 0.005\% \cdot h^{-1}$  in rested and exercised muscle,

442 respectively, in MYCO. The increase in mixed muscle FSR was greater in the MYCO  
443 condition compared with MILK condition (treatment  $\times$  time interaction effect;  $P=0.0199$ ),  
444 with the divergence located as trends for a difference between conditions in the  
445 postabsorptive ( $P=0.0890$ ) and postprandial FSRs ( $P=0.0930$ ) (**A**). These trends resulted in  
446 the delta postabsorptive to postprandial rise in mixed muscle FSR being greater in MYCO  
447 compared with MILK (treatment effect;  $P=0.0084$ ) (**B**). The group differences became more  
448 pronounced when comparing muscle FSRs derived from the L-[ring- $^2$ H $_5$ ]phenylalanine  
449 intracellular precursor pool. While main effects of exercise or any exercise interactions were  
450 still absent (all  $P>0.05$ ), protein ingestion increased FSR (time effect;  $P=0.0003$ ) and to a  
451 greater extent in MYCO compared with MILK (treatment  $\times$  time interaction effect;  
452  $P=0.0225$ ). Specifically, MYCO ingestion stimulated mixed muscle FSR (from to  
453  $0.031\pm 0.007$  to  $0.070\pm 0.006\% \cdot h^{-1}$  in rested, and  $0.028\pm 0.008$  to  $0.082\pm 0.008\% \cdot h^{-1}$  in  
454 exercised muscle;  $P<0.0001$ ), whereas MILK ingestion only trended to stimulate FSR (from  
455  $0.040\pm 0.010$  to  $0.060\pm 0.007\% \cdot h^{-1}$  in rested, and  $0.050\pm 0.012$  to  $0.058\pm 0.007\% \cdot h^{-1}$  in  
456 exercised muscle;  $P=0.060$ ).

457

#### 458 *Skeletal muscle cell signalling responses*

459 Skeletal muscle mTOR phosphorylation status was determined in  $n=15$  due to restrictions on  
460 remaining muscle tissue (final analysis therefore; MILK=7, MYCO=8) (**Figure 7**). Fold  
461 change with protein ingestion in muscle mTOR phosphorylation status did not differ between  
462 conditions (treatment effect;  $P>0.05$ ), was unaffected by exercise ( $P>0.05$ ), and did not show  
463 an interaction effect ( $P>0.05$ ).

464 Of the 46 genes analysed for their muscle mRNA expression (see **Table 4**), 19 genes showed  
465 no changes with exercise, protein ingestion, protein condition, or any interactions (all  
466  $P>0.05$ ; data not shown). Twenty seven genes responded to protein ingestion and/or exercise,

467 and the muscle mRNA expression of these genes are displayed in **Figure 8**. Specifically,  
468 protein ingestion either decreased (IRS1, TSC1, TSC2, CASTOR1, FOXO3, CAPN1, SRF,  
469 SLC7A8, SLC38A10, DDIT4, TRIM63 and SLC38A2) or increased (AKT1S1 and  
470 SLC38A9) muscle mRNA expression of some genes. Similarly, exercise decreased (SMAD2,  
471 PIK3R1, RPS6KB1, TFEB, MSTN, SLC38A2 and TRIM32) or increased (FBXO32,  
472 SLC7A1, and TRIM63) the muscle mRNA expression of some genes. Fifteen genes exhibited  
473 a time  $\times$  exercise interaction ( $P < 0.05$ ) such that EIF4E and TGFb1 mRNA expression  
474 increased in exercised muscle only, and DDIT4L and MSTN mRNA expression increased in  
475 rested muscle only ( $P < 0.05$ ). FBXO32, MSTN, TRIM63 mRNA expression decreased in  
476 rested muscle only, and SLC38A10, DDIT4, SLC38A2, and TRIM32 mRNA expression  
477 decreased in exercised muscle only ( $P < 0.05$ ). Only a single gene, TRIM32, showed a  
478 differential response between nutritional conditions, with its muscle mRNA expression  
479 greater in MILK compared with MYCO (treatment effect;  $P < 0.05$ ), which was driven by a  
480 greater expression in MILK compared with MYCO in the postprandial state ( $P < 0.01$ ).

## 481 **Discussion**

482 We assessed *in vivo* protein synthetic responses to the ingestion of leucine matched boluses  
483 of milk protein and mycoprotein within resting and exercised skeletal muscle, in healthy and  
484 trained, young men. In support of our initial hypothesis, mycoprotein ingestion robustly  
485 stimulated protein synthesis rates in resting and exercised muscle. Mycoprotein ingestion  
486 resulted in slower and lower rises in plasma amino acid (and leucine) concentrations  
487 compared with the ingestion of milk protein. Despite this, and contrary to our secondary  
488 hypothesis, we report that mycoprotein ingestion stimulated muscle protein synthesis rates to  
489 a greater extent when compared with milk protein.

490 Previous work has suggested that the rate and/or magnitude of plasma essential  
491 aminoacidemia and leucinemia following dietary protein ingestion are the key determinants  
492 that modulate postprandial muscle protein synthesis rates (2, 6, 24, 35-37). As expected (23),  
493 we observed more rapid protein digestion and intestinal amino acid absorption rates  
494 following milk compared with mycoprotein ingestion, as evidenced by larger and more rapid  
495 postprandial aminoacidemia and leucinemia (Figures 2A-D). As a consequence, milk protein  
496 ingestion resulted in a quicker rise in circulating insulin concentrations (Figure 3A), also a  
497 postprandial systemic condition expected to facilitate muscle protein anabolism (38). In line  
498 with our hypothesis, we observed a robust stimulation of mixed muscle protein synthesis  
499 rates in response to both protein sources (Figure 6A). However, we report a greater  
500 stimulation of mixed muscle protein synthesis rates following mycoprotein compared with  
501 milk protein ingestion (Figure 6A). Moreover, when expressing these data as the change in  
502 muscle protein synthesis rates from postabsorptive to postprandial (Figure 6B), the response  
503 to mycoprotein ingestion was more than double that of milk protein ingestion. Given this  
504 response occurred despite 'inferior' postprandial plasma amino acid kinetics, it is of interest  
505 to consider *why* this was observed.

506 In studies where isolated protein sources are ingested (i.e. with little or no additional  
507 macronutrients), the rate and/or magnitude of leucinemia generally predicts subsequent rates  
508 of muscle protein synthesis (2, 24, 35, 36). However, in studies where protein was co-  
509 ingested with carbohydrate or fat, plasma leucine concentrations were less predictive of the  
510 subsequent muscle protein synthetic response. For example, carbohydrate co-ingestion can  
511 markedly attenuate the peak (and total) magnitude of postprandial leucinemia, but does not  
512 inhibit the muscle protein synthetic response compared with protein ingestion alone (39-42).  
513 This suggests, within the context of a mixed meal, plasma leucine kinetics alone do not  
514 dictate the postprandial muscle protein synthetic response. Further, co-ingestion of additional  
515 macronutrients *per se* do not confer additional stimulation of muscle protein synthesis rates  
516 (39-42), and therefore neither the additional macronutrients nor energy content of the  
517 mycoprotein can (solely) explain its *greater* anabolic response in the present study. In line  
518 with our findings, a recent study reported that protein consumed within a 'whole food' matrix  
519 (i.e. whole eggs) led to a delayed and lower peak magnitude of postprandial leucinemia, but  
520 *greater* rates of postprandial muscle protein synthesis compared with the protein ingested  
521 within the egg white only (21). It is therefore possible that the present data, and those from  
522 van Vliet and colleagues (21), are a result of a potentiating effect of consuming protein within  
523 a more complete food matrix/whole food meal. Whether this is an effect of the food matrix  
524 *per se* (42), a combined effect of the presence of additional macronutrients (or their specific  
525 subclasses (43-45)), fibre (mycoprotein is high in fibre composed of a 2:1 ratio of  $\beta$ -glucan  
526 and chitin), higher energy content, or an effect of other (micronutrient) factors (46-48) is  
527 unclear but clearly warrants future investigation.

528 To investigate how mycoprotein enabled such a potent muscle protein synthetic response, we  
529 used the remaining muscle tissue to probe various myocellular signalling responses (Figure 7  
530 and 8). Aside from amino acids, it has been suggested that systemic rises in non-protein

531 nutrients (e.g. specific lipids (43, 45)), micronutrients (46)) may also exert influence over  
532 mTOR, the central molecular signalling pathway controlling muscle protein synthesis (49).  
533 Despite the divergent amino acid (and presumably other nutrients) profiles across the two  
534 nutritional conditions we observed no differences between groups in postprandial mTOR  
535 phosphorylation. We cannot discount the possibility that mTOR phosphorylation may have  
536 differed during the early postprandial period (50-52), that the translocation and subcellular  
537 location of mTOR may have differed across conditions (44), that investigating different  
538 phosphorylation sites may have yielded different results (53), that downstream targets of  
539 mTOR may have differed independently, or that our data are not appropriately powered to  
540 detect small, but physiologically relevant differences in phosphorylation status (particularly  
541 given we did not have a complete dataset due to limited tissue availability). Moreover, it is  
542 possible that the translocation and/or subcellular location of mTOR may have differed across  
543 conditions (44). Indeed, recent data suggest the subcellular locality of mTOR is important in  
544 regulating the (postprandial) muscle protein synthetic response (54, 55), and that non-protein  
545 dietary components may influence translocation and the regulation of post-exercise mRNA  
546 translation (44).

547 To gain insight into the potential adaptive response of the cell we examined the muscle  
548 postprandial and post-exercise transcriptional response. Exercise and protein ingestion  
549 resulted in a coordinated transcriptional response, demonstrated by the mRNA expression of  
550 27 of the 46 genes of interest changing 4 h post protein ingestion with/without exercise. The  
551 upregulation in expression of genes involved in amino acid transport (e.g. CAT1, LAT2,  
552 SNAT2) and protein synthesis (e.g. TSC1, TSC2, DDIT4) underline the rapid transcriptional  
553 responses that occur with nutrition and exercise (10, 56-60) which, at least in part, restore  
554 cellular homeostasis and direct the adaptive response. Additionally, the early inhibition of  
555 myostatin expression with exercise supports the concept that low myostatin expression

556 facilitates an anabolic environment (61). Only a single gene, the E3 ubiquitin ligase TRIM32,  
557 differentially responded to the different protein sources; being expressed to a lesser degree  
558 following mycoprotein ingestion. TRIM32 preferentially ubiquitinates actin and desmin  
559 filaments, with reduced levels of TRIM32 reducing the loss of these proteins (62, 63). This  
560 may be indicative of a more potent ability of mycoprotein to suppress excessive post-exercise  
561 muscle protein breakdown, although given the lack of a coordinated response of other  
562 proteolytic genes (e.g. MAFBx, MuRF1 etc.) this remains conjectural. Clearly, the ability of  
563 prolonged mycoprotein consumption to support resistance training-induced hypertrophy  
564 warrants future investigation. Worthy of note is one caveat of interpreting our cell signalling  
565 data in the present work is the increased risk of making a type 1 error due to due to multiple  
566 testing outcomes.

567 Two other factors that could have contributed to our findings are worthy of consideration.  
568 First, the mycoprotein drink contained ~20% more protein than the milk protein beverage  
569 (31.5 vs 26.2 g). In young men the muscle protein synthetic response to dietary protein  
570 ingestion plateaus at ~20 g protein (3, 11) (or 0.3 g·kg<sup>-1</sup>; (26)), which appears to be more due  
571 to leucine content, rather than total protein *per se* (64), at least when ample protein is  
572 provided (65). We therefore assume, since we fed in excess of 20 g / 0.3 g·kg<sup>-1</sup> in both  
573 conditions, that ample protein was available to negate protein *amount* being a significant  
574 contributing factor. In agreement, systemic amino acid concentrations were *lower* following  
575 mycoprotein compared with milk protein ingestion, again indicating non-protein/amino acid  
576 factors are likely responsible for the greater muscle protein synthetic effect of mycoprotein.  
577 Second, whilst it is generally assumed that leucine (and the other BCAAs) is the primary  
578 nutritional anabolic trigger (6, 25, 64, 66), it is clear that other essential amino acids (50),  
579 such as arginine (67-69), may also play a role in initiating muscle protein synthesis rates.  
580 Therefore, it is also plausible that the amino acid profile of mycoprotein was simply more

581 anabolic than milk protein. This, however, would be contrary to the consensus of *in vivo*  
582 human data (22), and necessitate that specific amino acids, with a greater preponderance in  
583 the mycoprotein drink, possess anabolic signalling roles that are as yet undocumented in  
584 humans.

585 To conclude, the bolus consumption of mycoprotein stimulated resting and post-exercise  
586 muscle protein synthesis rates in young men, and to a greater extent than a leucine-matched  
587 bolus of milk protein. These novel data show mycoprotein represents a viable, sustainably  
588 produced non-animal derived alternative dietary protein source to support acute tissue  
589 remodelling in response to exercise. Our work implies that mycoprotein could be  
590 incorporated into the habitual diet of those undertaking prolonged resistance training to  
591 facilitate muscle hypertrophic responses.

592

593 Acknowledgements

594 The authors would like to acknowledge Geping Fang and Shriners Hospitals for Children  
595 (grant #84090) for their technical assistance, Dr Mike Jordan of Premier Analytical services  
596 for analysing the nutritional composition of the experimental proteins. The authors would  
597 also like to thank Andrew Davenport for his assistance in preparing the manuscript.

598 The project was sponsored by Marlow Foods Ltd (BTW as grant holder). The University of  
599 Exeter (BTW) were responsible for the study design, data collection and analysis, decision to  
600 publish and preparation of the manuscript. The private partners have contributed to the  
601 project through regular discussion. AJM and MOCC are supported from a studentship grant  
602 in collaboration with Marlow Foods.

603 The authors' contributions were as follows: AJM, BTW, MLD and FBT designed the  
604 research; AJM, MLD and SRJ conducted the research; AJM, JRB and DRA performed the  
605 biological analysis; AJM and BTW analysed the data and wrote the manuscript. BTW has  
606 primary responsibility for the final content. All authors have read and approved the final  
607 content. TJAF is an employee of Marlow Foods, BTW, SRJ, JRB, MLD, FBS are employees  
608 of the University of Exeter. Aside from those mentioned above, the authors declare that there  
609 are no conflicts of interest.

## References

1. Tang JE, Moore DR, Kujbida GW, Tarnopolsky MA, Phillips SM. Ingestion of whey hydrolysate, casein, or soy protein isolate: effects on mixed muscle protein synthesis at rest and following resistance exercise in young men. *Journal of Applied Physiology* 2009;107(3):987-92. doi: 10.1152/jappphysiol.00076.2009.
2. Pennings B, Boirie Y, Senden JM, Gijsen AP, Kuipers H, van Loon LJ. Whey protein stimulates postprandial muscle protein accretion more effectively than do casein and casein hydrolysate in older men. *The American Journal of Clinical Nutrition* 2011;93(5):997-1005. doi: 10.3945/ajcn.110.008102.
3. Moore DR, Robinson MJ, Fry JL, Tang JE, Glover EI, Wilkinson SB, Prior T, Tarnopolsky MA, Phillips SM. Ingested protein dose response of muscle and albumin protein synthesis after resistance exercise in young men. *The American Journal of Clinical Nutrition* 2008;89(1):161-8.
4. Tipton KD, Gurkin BE, Matin S, Wolfe RR. Nonessential amino acids are not necessary to stimulate net muscle protein synthesis in healthy volunteers. *The Journal of Nutritional Biochemistry* 1999;10(2):89-95.
5. Wall BT, Hamer HM, de Lange A, Kiskini A, Groen BBL, Senden JMG, Gijsen AP, Verdijk LB, van Loon LJC. Leucine co-ingestion improves post-prandial muscle protein accretion in elderly men. *Clinical Nutrition* 2013;32(3):412-9. doi: 10.1016/j.clnu.2012.09.002.
6. Norton LE, Layman DK, Bunpo P, Anthony TG, Brana DV, Garlick PJ. The leucine content of a complete meal directs peak activation but not duration of skeletal muscle protein synthesis and mammalian target of rapamycin signaling in rats. *The Journal of Nutrition* 2009;139(6):1103-9. doi: 10.3945/jn.108.103853.

7. Phillips SM, Tipton KD, Aarsland A, Wolf SE, Wolfe RR. Mixed muscle protein synthesis and breakdown after resistance exercise in humans. *American Journal of Physiology-Endocrinology and Metabolism* 1997;273(1):E99-E107.
8. Biolo G, Maggi SP, Williams BD, Tipton KD, Wolfe RR. Increased rates of muscle protein turnover and amino acid transport after resistance exercise in humans. *The American Journal of Physiology* 1995;268(3 Pt 1):E514-20. doi:  
10.1152/ajpendo.1995.268.3.E514.
9. Areta JL, Burke LM, Ross ML, Camera DM, West DW, Broad EM, Jeacocke NA, Moore DR, Stellingwerff T, Phillips SM, et al. Timing and distribution of protein ingestion during prolonged recovery from resistance exercise alters myofibrillar protein synthesis. *The Journal of Physiology* 2013;591(9):2319-31. doi:  
10.1113/jphysiol.2012.244897.
10. Wall BT, Burd NA, Franssen R, Gorissen SH, Snijders T, Senden JM, Gijsen AP, van Loon LJ. Presleep protein ingestion does not compromise the muscle protein synthetic response to protein ingested the following morning. *American Journal of Physiology Endocrinology and Metabolism* 2016;311(6):E964-e73. doi:  
10.1152/ajpendo.00325.2016.
11. Witard OC, Jackman SR, Breen L, Smith K, Selby A, Tipton KD. Myofibrillar muscle protein synthesis rates subsequent to a meal in response to increasing doses of whey protein at rest and after resistance exercise. *The American Journal of Clinical Nutrition* 2013;99(1):86-95.
12. Rasmussen BB, Tipton KD, Miller SL, Wolf SE, Wolfe RR. An oral essential amino acid-carbohydrate supplement enhances muscle protein anabolism after resistance exercise. *Journal of Applied Physiology* 2000;88(2):386-92. doi:  
10.1152/jappl.2000.88.2.386.

13. Gorissen SH, Horstman AM, Franssen R, Crombag JJ, Langer H, Bierau J, Respondek F, van Loon LJ. Ingestion of Wheat Protein Increases In Vivo Muscle Protein Synthesis Rates in Healthy Older Men in a Randomized Trial. *The Journal of Nutrition* 2016;146(9):1651-9. doi: 10.3945/jn.116.231340.
14. Yang Y, Churchward-Venne TA, Burd NA, Breen L, Tarnopolsky MA, Phillips SM. Myofibrillar protein synthesis following ingestion of soy protein isolate at rest and after resistance exercise in elderly men. *Nutrition & Metabolism* 2012;9(1):57. doi: 10.1186/1743-7075-9-57.
15. Groen BB, Horstman AM, Hamer HM, de Haan M, van Kranenburg J, Bierau J, Poeze M, Wodzig WK, Rasmussen BB, van Loon LJ. Post-Prandial Protein Handling: You Are What You Just Ate. *PloS one* 2015;10(11):e0141582. doi: 10.1371/journal.pone.0141582.
16. Mitchell CJ, McGregor RA, D'Souza RF, Thorstensen EB, Markworth JF, Fanning AC, Poppitt SD, Cameron-Smith D. Consumption of Milk Protein or Whey Protein Results in a Similar Increase in Muscle Protein Synthesis in Middle Aged Men. *Nutrients* 2015;7(10):8685-99. doi: 10.3390/nu7105420.
17. Burd NA, Gorissen SH, van Vliet S, Snijders T, van Loon LJ. Differences in postprandial protein handling after beef compared with milk ingestion during postexercise recovery: a randomized controlled trial. *The American Journal of Clinical Nutrition* 2015;102(4):828-36. doi: 10.3945/ajcn.114.103184.
18. Symons TB, Sheffield-Moore M, Wolfe RR, Paddon-Jones D. A moderate serving of high-quality protein maximally stimulates skeletal muscle protein synthesis in young and elderly subjects. *Journal of the American Dietetic Association* 2009;109(9):1582-6. doi: 10.1016/j.jada.2009.06.369.

19. Robinson MJ, Burd NA, Breen L, Rerecich T, Yang Y, Hector AJ, Baker SK, Phillips SM. Dose-dependent responses of myofibrillar protein synthesis with beef ingestion are enhanced with resistance exercise in middle-aged men. *Applied Physiology, Nutrition, and Metabolism* 2013;38(2):120-5. doi: 10.1139/apnm-2012-0092.
20. Pennings B, Groen BB, van Dijk JW, de Lange A, Kiskini A, Kuklinski M, Senden JM, van Loon LJ. Minced beef is more rapidly digested and absorbed than beef steak, resulting in greater postprandial protein retention in older men. *The American Journal of Clinical Nutrition* 2013;98(1):121-8. doi: 10.3945/ajcn.112.051201.
21. van Vliet S, Shy EL, Abou Sawan S, Beals JW, West DW, Skinner SK, Ulanov AV, Li Z, Paluska SA, Parsons CM, et al. Consumption of whole eggs promotes greater stimulation of postexercise muscle protein synthesis than consumption of isonitrogenous amounts of egg whites in young men. *The American Journal of Clinical Nutrition* 2017;106(6):1401-12. doi: 10.3945/ajcn.117.159855.
22. van Vliet S, Burd NA, van Loon LJ. The Skeletal Muscle Anabolic Response to Plant- versus Animal-Based Protein Consumption. *The Journal of Nutrition* 2015;145(9):1981-91. doi: 10.3945/jn.114.204305.
23. Dunlop MV, Kilroe SP, Bowtell JL, Finnigan TJ, Salmon DL, Wall BT. Mycoprotein represents a bioavailable and insulinotropic non-animal-derived dietary protein source: a dose–response study. *British Journal of Nutrition* 2017;118(9):673-85.
24. Tang JE, Moore DR, Kujbida GW, Tarnopolsky MA, Phillips SM. Ingestion of whey hydrolysate, casein, or soy protein isolate: effects on mixed muscle protein synthesis at rest and following resistance exercise in young men. *Journal of Applied Physiology* 2009;107(3):987-92. doi: 10.1152/jappphysiol.00076.2009.
25. Churchward-Venne TA, Breen L, Di Donato DM, Hector AJ, Mitchell CJ, Moore DR, Stellingwerff T, Breuille D, Offord EA, Baker SK, et al. Leucine supplementation of a

- low-protein mixed macronutrient beverage enhances myofibrillar protein synthesis in young men: a double-blind, randomized trial. *The American Journal of Clinical Nutrition* 2014;99(2):276-86. doi: 10.3945/ajcn.113.068775.
26. Stokes T, Hector AJ, Morton RW, McGlory C, Phillips SM. Recent Perspectives Regarding the Role of Dietary Protein for the Promotion of Muscle Hypertrophy with Resistance Exercise Training. *Nutrients* 2018;10(2). doi: 10.3390/nu10020180.
  27. Abumrad NN, Rabin D, Diamond MP, Lacy WW. Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man. *Metabolism: Clinical and Experimental* 1981;30(9):936-40.
  28. Wolfe RR, Chinkes DL. *Isotope tracers in metabolic research: principles and practice of kinetic analysis*: John Wiley & Sons, 2005.
  29. Bornø A, Hulston CJ, van Hall G. Determination of human muscle protein fractional synthesis rate: an evaluation of different mass spectrometry techniques and considerations for tracer choice. *Journal of Mass Spectrometry* 2014;49(8):674-80. doi: 10.1002/jms.3387.
  30. Zabielski P, Ford GC, Persson XM, Jaleel A, Dewey JD, Nair KS. Comparison of different mass spectrometry techniques in the measurement of L-[ring-<sup>13</sup>C<sub>6</sub>]phenylalanine incorporation into mixed muscle proteins. *Journal of Mass Spectrometry* 2013;48(2):269-75. doi: 10.1002/jms.3120.
  31. Dirks ML, Stephens FB, Jackman SR, Galera Gordo J, Machin DJ, Pulsford RM, van Loon LJC, Wall BT. A single day of bed rest, irrespective of energy balance, does not affect skeletal muscle gene expression or insulin sensitivity. *Experimental Physiology* 2018;103(6):860-75. doi: 10.1113/ep086961.

32. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Analytical Biochemistry* 1987;162(1):156-9. doi: 10.1006/abio.1987.9999.
33. Tsintzas K, Jewell K, Kamran M, Laithwaite D, Boonsong T, Littlewood J, Macdonald I, Bennett A. Differential regulation of metabolic genes in skeletal muscle during starvation and refeeding in humans. *The Journal of Physiology* 2006;575(Pt 1):291-303. doi: 10.1113/jphysiol.2006.109892.
34. Gorissen SHM, Burd NA, Kramer IF, van Kranenburg J, Gijsen AP, Rooyackers O, van Loon LJC. Co-ingesting milk fat with micellar casein does not affect postprandial protein handling in healthy older men. *Clinical Nutrition* 2017;36(2):429-37. doi: 10.1016/j.clnu.2015.12.011.
35. Koopman R, Crombach N, Gijsen AP, Walrand S, Fauquant J, Kies AK, Lemosquet S, Saris WH, Boirie Y, van Loon LJ. Ingestion of a protein hydrolysate is accompanied by an accelerated in vivo digestion and absorption rate when compared with its intact protein. *The American Journal of Clinical Nutrition* 2009;90(1):106-15. doi: 10.3945/ajcn.2009.27474.
36. Burd NA, Yang Y, Moore DR, Tang JE, Tarnopolsky MA, Phillips SM. Greater stimulation of myofibrillar protein synthesis with ingestion of whey protein isolate v. micellar casein at rest and after resistance exercise in elderly men. *The British Journal of Nutrition* 2012;108(6):958-62. doi: 10.1017/s0007114511006271.
37. Phillips SM. The impact of protein quality on the promotion of resistance exercise-induced changes in muscle mass. *Nutrition & Metabolism* 2016;13:64. doi: 10.1186/s12986-016-0124-8.

38. Abdulla H, Smith K, Atherton PJ, Idris I. Role of insulin in the regulation of human skeletal muscle protein synthesis and breakdown: a systematic review and meta-analysis. *Diabetologia* 2016;59(1):44-55. doi: 10.1007/s00125-015-3751-0.
39. Gorissen SH, Burd NA, Hamer HM, Gijsen AP, Groen BB, van Loon LJ. Carbohydrate coingestion delays dietary protein digestion and absorption but does not modulate postprandial muscle protein accretion. *The Journal of Clinical Endocrinology and Metabolism* 2014;99(6):2250-8. doi: 10.1210/jc.2013-3970.
40. Hamer HM, Wall BT, Kiskini A, de Lange A, Groen BB, Bakker JA, Gijsen AP, Verdijk LB, van Loon LJ. Carbohydrate co-ingestion with protein does not further augment post-prandial muscle protein accretion in older men. *Nutrition & Metabolism* 2013;10(1):15. doi: 10.1186/1743-7075-10-15.
41. Koopman R, Beelen M, Stellingwerff T, Pennings B, Saris WH, Kies AK, Kuipers H, van Loon LJ. Coingestion of carbohydrate with protein does not further augment postexercise muscle protein synthesis. *American Journal of Physiology Endocrinology and Metabolism* 2007;293(3):E833-42. doi: 10.1152/ajpendo.00135.2007.
42. Churchward-Venne TA, Snijders T, Linkens AM, Hamer HM, van Kranenburg J, van Loon LJ. Ingestion of Casein in a Milk Matrix Modulates Dietary Protein Digestion and Absorption Kinetics but Does Not Modulate Postprandial Muscle Protein Synthesis in Older Men. *Journal of Nutrition* 2015;145(7):1438-45. doi: 10.3945/jn.115.213710.
43. Castellano BM, Thelen AM, Moldavski O, Feltes M, van der Welle RE, Mydock-McGrane L, Jiang X, van Eijkeren RJ, Davis OB, Louie SM, et al. Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex. *Science* 2017;355(6331):1306-11. doi: 10.1126/science.aag1417.

44. Abou Sawan S, van Vliet S, West DWD, Beals JW, Paluska SA, Burd NA, Moore DR. Whole egg, but not egg white, ingestion induces mTOR colocalization with the lysosome after resistance exercise. *American Journal of Physiology-Cell physiology* 2018;315(4):C537-c43. doi: 10.1152/ajpcell.00225.2018.
45. Yasuda M, Tanaka Y, Kume S, Morita Y, Chin-Kanasaki M, Araki H, Isshiki K, Araki S, Koya D, Haneda M, et al. Fatty acids are novel nutrient factors to regulate mTORC1 lysosomal localization and apoptosis in podocytes. *Biochim Biophys Acta-Molecular Basis of Disease* 2014;1842(7):1097-108. doi: 10.1016/j.bbadis.2014.04.001.
46. Salles J, Chanet A, Giraudet C, Patrac V, Pierre P, Jourdan M, Luiking YC, Verlaan S, Migne C, Boirie Y, et al. 1,25(OH)<sub>2</sub>-vitamin D<sub>3</sub> enhances the stimulating effect of leucine and insulin on protein synthesis rate through Akt/PKB and mTOR mediated pathways in murine C2C12 skeletal myotubes. *Molecular Nutrition and Food Research* 2013;57(12):2137-46. doi: 10.1002/mnfr.201300074.
47. Zhao Z, Barcus M, Kim J, Lum KL, Mills C, Lei XG. High Dietary Selenium Intake Alters Lipid Metabolism and Protein Synthesis in Liver and Muscle of Pigs. *The Journal of Nutrition* 2016;146(9):1625-33. doi: 10.3945/jn.116.229955.
48. Marzani B, Balage M, Venien A, Astruc T, Papet I, Dardevet D, Mosoni L. Antioxidant supplementation restores defective leucine stimulation of protein synthesis in skeletal muscle from old rats. *The Journal of Nutrition* 2008;138(11):2205-11. doi: 10.3945/jn.108.094029.
49. Walker DK, Dickinson JM, Timmerman KL, Drummond MJ, Reidy PT, Fry CS, Gundermann DM, Rasmussen BB. Exercise, amino acids, and aging in the control of human muscle protein synthesis. *Medicine and Science in Sports and Exercise* 2011;43(12):2249-58. doi: 10.1249/MSS.0b013e318223b037.

50. Churchward-Venne TA, Burd NA, Mitchell CJ, West DW, Philp A, Marcotte GR, Baker SK, Baar K, Phillips SM. Supplementation of a suboptimal protein dose with leucine or essential amino acids: effects on myofibrillar protein synthesis at rest and following resistance exercise in men. *The Journal of Physiology* 2012;590(11):2751-65. doi: 10.1113/jphysiol.2012.228833.
51. Drummond MJ, Dickinson JM, Fry CS, Walker DK, Gundermann DM, Reidy PT, Timmerman KL, Markofski MM, Paddon-Jones D, Rasmussen BB, et al. Bed rest impairs skeletal muscle amino acid transporter expression, mTORC1 signaling, and protein synthesis in response to essential amino acids in older adults. *American Journal of Physiology Endocrinology and Metabolism* 2012;302(9):E1113-22. doi: 10.1152/ajpendo.00603.2011.
52. West DW, Burd NA, Coffey VG, Baker SK, Burke LM, Hawley JA, Moore DR, Stellingwerff T, Phillips SM. Rapid aminoacidemia enhances myofibrillar protein synthesis and anabolic intramuscular signaling responses after resistance exercise. *The American Journal of Clinical Nutrition* 2011;94(3):795-803. doi: 10.3945/ajcn.111.013722.
53. Figueiredo VC, Dungan CM, Peterson CA, McCarthy JJ. On the appropriateness of antibody selection to estimate mTORC1 activity. *Acta Physiologica* 2019:e13354. doi: 10.1111/apha.13354.
54. Hodson N, McGlory C, Oikawa SY, Jeromson S, Song Z, Ruegg MA, Hamilton DL, Phillips SM, Philp A. Differential localization and anabolic responsiveness of mTOR complexes in human skeletal muscle in response to feeding and exercise. *American Journal of Physiology-Cell Physiology* 2017;313(6):C604-c11. doi: 10.1152/ajpcell.00176.2017.

55. Abou Sawan S, van Vliet S, Parel JT, Beals JW, Mazzulla M, West DWD, Philp A, Li Z, Paluska SA, Burd NA, et al. Translocation and protein complex co-localization of mTOR is associated with postprandial myofibrillar protein synthesis at rest and after endurance exercise. *Physiological Reports* 2018;6(5). doi: 10.14814/phy2.13628.
56. Graber TG, Borack MS, Reidy PT, Volpi E, Rasmussen BB. Essential amino acid ingestion alters expression of genes associated with amino acid sensing, transport, and mTORC1 regulation in human skeletal muscle. *Nutrition & Metabolism* 2017;14:35. doi: 10.1186/s12986-017-0187-1.
57. Wall BT, Dirks ML, Snijders T, van Dijk JW, Fritsch M, Verdijk LB, van Loon LJ. Short-term muscle disuse lowers myofibrillar protein synthesis rates and induces anabolic resistance to protein ingestion. *American Journal of Physiology Endocrinology and Metabolism* 2016;310(2):E137-47. doi: 10.1152/ajpendo.00227.2015.
58. Drummond MJ, Fry CS, Glynn EL, Timmerman KL, Dickinson JM, Walker DK, Gundersmann DM, Volpi E, Rasmussen BB. Skeletal muscle amino acid transporter expression is increased in young and older adults following resistance exercise. *Journal of Applied Physiology* 2011;111(1):135-42. doi: 10.1152/jappphysiol.01408.2010.
59. Reidy PT, Walker DK, Dickinson JM, Gundersmann DM, Drummond MJ, Timmerman KL, Cope MB, Mukherjea R, Jennings K, Volpi E, et al. Soy-dairy protein blend and whey protein ingestion after resistance exercise increases amino acid transport and transporter expression in human skeletal muscle. *Journal of Applied Physiology* 2014;116(11):1353-64. doi: 10.1152/jappphysiol.01093.2013.
60. Mitchell CJ, Zeng N, D'Souza RF, Mitchell SM, Aasen K, Fanning AC, Poppitt SD, Cameron-Smith D. Minimal dose of milk protein concentrate to enhance the anabolic

signalling response to a single bout of resistance exercise; a randomised controlled trial. *Journal of the International Society of Sports Nutrition* 2017;14:17. doi: 10.1186/s12970-017-0175-x.

61. Rodriguez J, Vernus B, Chelh I, Cassar-Malek I, Gabillard JC, Hadj Sassi A, Seiliez I, Picard B, Bonnieu A. Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. *Cellular and Molecular Life Sciences : CMLS* 2014;71(22):4361-71. doi: 10.1007/s00018-014-1689-x.
62. Cohen S, Zhai B, Gygi SP, Goldberg AL. Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. *The Journal of Cell Biology* 2012;198(4):575-89. doi: 10.1083/jcb.201110067.
63. Kudryashova E, Kudryashov D, Kramerova I, Spencer MJ. Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin. *Journal of Molecular Biology* 2005;354(2):413-24. doi: 10.1016/j.jmb.2005.09.068.
64. Devries MC, McGlory C, Bolster DR, Kamil A, Rahn M, Harkness L, Baker SK, Phillips SM. Leucine, Not Total Protein, Content of a Supplement Is the Primary Determinant of Muscle Protein Anabolic Responses in Healthy Older Women. *The Journal of Nutrition* 2018;148(7):1088-95. doi: 10.1093/jn/nxy091.
65. Fuchs CJ, Hermans WJH, Holwerda AM, Smeets JSJ, Senden JM, van Kranenburg J, Gijsen AP, Wodzig W, Schierbeek H, Verdijk LB, et al. Branched-chain amino acid and branched-chain ketoacid ingestion increases muscle protein synthesis rates in vivo in older adults: a double-blind, randomized trial. *The American Journal of Clinical Nutrition* 2019. doi: 10.1093/ajcn/nqz120.

66. Crozier SJ, Kimball SR, Emmert SW, Anthony JC, Jefferson LS. Oral leucine administration stimulates protein synthesis in rat skeletal muscle. *The Journal of Nutrition* 2005;135(3):376-82. doi: 10.1093/jn/135.3.376.
67. Saxton RA, Chantranupong L, Knockenhauer KE, Schwartz TU, Sabatini DM. Mechanism of arginine sensing by CASTOR1 upstream of mTORC1. *Nature* 2016;536(7615):229-33. doi: 10.1038/nature19079.
68. Chantranupong L, Scaria SM, Saxton RA, Gygi MP, Shen K, Wyant GA, Wang T, Harper JW, Gygi SP, Sabatini DM. The CASTOR Proteins Are Arginine Sensors for the mTORC1 Pathway. *Cell* 2016;165(1):153-64. doi: 10.1016/j.cell.2016.02.035.
69. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. *Cell* 2017;168(6):960-76. doi: 10.1016/j.cell.2017.02.004.

## Tables

**Table 1.** Participant characteristics.

	<b>MILK</b>	<b>MYCO</b>
	( <i>n</i> = 10)	( <i>n</i> = 10)
<b>Age (y)</b>	22 ± 1	22 ± 1
<b>Body mass (kg)</b>	84 ± 3	81 ± 3
<b>Height (cm)</b>	178 ± 2	182 ± 3
<b>BMI (kg·m<sup>-2</sup>)</b>	26 ± 1	25 ± 1
<b>Fat (% body mass)</b>	12 ± 2	9 ± 2
<b>Lean mass (kg)</b>	73 ± 3	73 ± 2
<b>Total work done (J)</b>	29540 ± 1782	30722 ± 2059
<b>Energy (MJ·day<sup>-1</sup>)</b>	9.5 ± 0.8	11.6 ± 0.9
<b>Protein (g·day<sup>-1</sup>)</b>	150 ± 20	162 ± 17
<b>Protein (g·kg<sup>-1</sup>·day<sup>-1</sup>)</b>	1.8 ± 0.2	2.1 ± 0.2

Values represent mean ± SEM. MILK, Milk protein ingestion condition; MYCO, mycoprotein ingestion condition, BMI, body mass index. Total work represents the amount of work done (in J) during the experimental exercise protocol. No statistically significant differences were observed between conditions ( $P > 0.05$ ).

**Table 2.** The nutritional content of the experimental drinks.

	MILK	MYCO
<b>Macronutrients</b>		
Protein (g)	26.2	31.5
Fat (g)	0.3	9
Carbohydrate (g)	1.7	7
Fibre (g)	<0.1	17.5
Energy (kcal)	108	238
Energy (kJ)	458	996
<b>Amino acid content (g)</b>		
Alanine	0.8	2.0
Arginine	0.9	2.2
Aspartic acid	1.9	3.3
Glutamic acid	5.8	3.9
Glycine	0.5	1.5
Histidine	0.8	0.8
Isoleucine	1.3	1.5
Leucine	2.5	2.5
Lysine	2.1	2.6
Phenylalanine	1.3	1.5
Proline	2.7	1.6
Serine	1.5	1.6
Threonine	1.1	1.7
Tryptophan	-	1.2
Tyrosine	1.3	1.2
Valine	1.7	1.9

Protein content (g) is calculated from the sum of amino acids measured after protein hydrolysis. The experimental drinks contained 31 g and 70 g of total product for MILK and MYCO, respectively.

**Table 3.** Muscle protein synthesis rates (FSR) before and after protein ingestion, and resistance exercise.

		<b>Postabsorptive</b>	<b>Postprandial</b>
<b>MILK</b>	Rested	0.036 ± 0.008	0.052 ± 0.006
( <i>n</i> = 10)	Exercised	0.035 ± 0.008	0.056 ± 0.005
<b>MYCO</b>	Rested	0.025 ± 0.006	0.057 ± 0.004
( <i>n</i> = 9)	Exercised	0.024 ± 0.007	0.072 ± 0.005

Values represent mean ± SEM. Mixed muscle protein fractional synthesis rates (FSRs; A) calculated from the plasma L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine precursor pool in the postabsorptive (fasted) and postprandial (fed) state, in rested and exercised (single bout of unilateral concentric leg extensions) muscle in healthy young men. Postprandial state represents a 4 h period following the ingestion of 26.2g milk protein (MILK; *n*=10) or 31.5g mycoprotein (MYCO; *n*=9). Data were analysed with three-way ANOVA. Time effect, *P*<0.0001; treatment effect, *P*=0.99; exercise effect, *P*=0.06; treatment × time, *P*=0.02; treatment × exercise, *P*=0.22; exercise × time, *P*=0.13; treatment × time × exercise, *P*=0.42.

**Table 4.** Names and symbols of gene expression assay targets that were preloaded on to the microfluidic cards.

<b>Gene name (human skeletal muscle)</b>	<b>Symbol</b>
Insulin Receptor substrate 1	IRS1
AKT serine/threonine kinase 1	AKT1
AKT serine/threonine kinase 2	AKT2
phosphoinositide-3-kinase regulatory subunit 1	PIK3R1
mechanistic target of rapamycin	MTOR
ribosomal protein S6 kinase B1	RPS6KB1
eukaryotic translation initiation factor 4E binding protein 1	EIF4EBP1
eukaryotic translation initiation factor 4 gamma 1	EIF4G1
eukaryotic translation initiation factor 4E	EIF4E
sestrin 2	SESN2
GATS protein like 3	GATSL3
leucyl-tRNA synthetase	LARS
MAP kinase interacting serine/threonine kinase 2	MKNK2
transcription factor EB	TFEB
tuberous sclerosis 1	TSC1
tuberous sclerosis 2	TSC2
DNA damage inducible transcript 4	DDIT4
DNA damage inducible transcript 4 like	DDIT4L
regulatory associated protein of MTOR complex 1	RPTOR
NPR2-like, GATOR1 complex subunit	NPRL2
AKT1 substrate 1	AKT1S1
forkhead box O1	FOXO1
forkhead box O3	FOXO3
forkhead box O4	FOXO4
calpain 1	CAPN1
calpain 3	CAPN3
caspase 3	CASP3

nuclear factor kappa B subunit 1	NFKB1
F-box protein 32	FBXO32
tripartite motif containing 63	TRIM63/MuRF1
tripartite motif containing 32	TRIM32
activating transcription factor 4	ATF4
Myostatin	MSTN
growth differentiation factor 11	GDF11
SMAD family member 2	SMAD2
SMAD family member 3	SMAD3
transforming growth factor beta 1	TGFB1
inhibin beta A subunit	INHBA
solute carrier family 7 member 5	SLC7A5
solute carrier family 7 member 8	SLC7A8/LAT2
solute carrier family 36 member 1	SLC36A1
solute carrier family 7 member 1	SLC7A1
solute carrier family 38 member 2	SLC38A2
solute carrier family 38 member 9	SLC38A9/SNAT9
solute carrier family 38 member 10	SLC38A10
serum response factor	SRF
glyceraldehyde-3-phosphate dehydrogenase	GAPDH
beta-2-microglobulin	B2M

## Figure Legends

**Figure 1.** Schematic representation of the experimental protocol.

**Figure 2.** The timecourse and incremental AUC (iAUC) of plasma total branched chain amino acid (A and B), leucine (C and D), isoleucine (E and F), valine (G and H), tyrosine (I and J) and phenylalanine (K and L) concentrations during a 3 h postabsorptive period (time-course graphs only) and a 4 h postprandial period in healthy young men. iAUC graphs represent total 4 h postprandial plasma concentrations above postabsorptive values. The vertical line on each graph indicates the transition from postabsorptive to postprandial conditions via the ingestion of 26.2g milk protein (MILK;  $n=10$ ) or 31.5g mycoprotein (MYCO;  $n=10$ ), where a single bout of unilateral leg extension exercise was also performed. Time-course and iAUC data were analysed with a repeated measures two-way ANOVA and independent t-tests, respectively, with Sidak's post hoc tests applied to locate individual differences ( $P \leq 0.05$ ). Values are means, with their standard errors represented by vertical bars. \* indicates individual differences between conditions at these time points, and a difference between conditions on the bar graphs. Treatment  $\times$  time interaction effect; all  $P < 0.0001$ .

**Figure 3.** The timecourse and incremental AUC (iAUC) of serum insulin concentrations during a 3 h postabsorptive period (time-course graph only) and a 4 h postprandial period in healthy young men, with iAUCs representing total 4 h postprandial plasma concentrations above postabsorptive values. The vertical line on each graph indicates the transition from postabsorptive to postprandial conditions via the ingestion of 26.2g milk protein (MILK;  $n=10$ ) or 31.5g mycoprotein (MYCO;  $n=10$ ), where a single bout of unilateral leg extension exercise was also performed. Data were analysed with a repeated measures two-way ANOVA and

independent t-tests, respectively, with Sidak's post hoc tests applied to locate individual differences ( $P \leq 0.05$ ). Values are means, with their standard errors represented by vertical bars.

\* indicates individual differences between conditions at these time points, and a difference between conditions on the bar graph. Treatment  $\times$  time interaction effect;  $P < 0.0001$ .

**Figure 4.** L-[ring- $^2\text{H}_5$ ]phenylalanine (A), L-[3,3- $^2\text{H}_2$ ]tyrosine (B), and L-[ring- $^2\text{H}_4$ ]-tyrosine (C) enrichments during a stable isotope experimental test day in healthy young men. The vertical line on each graph indicates the transition from postabsorptive to postprandial conditions via the ingestion of 26.2g milk protein (MILK;  $n=10$ ) or 31.5g mycoprotein (MYCO;  $n=10$ ), where a single bout of unilateral leg extension exercise was also performed. Data were analysed with a repeated measures two-way ANOVA, with Sidak's post hoc tests applied to locate individual differences ( $P \leq 0.05$ ). Values are means, with their standard errors represented by vertical bars. \* indicates different from fasting ( $t = 0$  min) for MYCO. Horizontal bar indicates a change from  $t=0$  across conditions. Treatment  $\times$  time interaction effect; A,  $P=0.0018$ ; B,  $P=0.5357$ ; C,  $P=0.0026$ .

**Figure 5.** Total phenylalanine rate of appearance (Ra; A), total phenylalanine rate of disappearance (Rd; B), and phenylalanine hydroxylation (C) during a 3 h postabsorptive period and a 4 h postprandial period in healthy young men. The vertical line on each graph indicates the transition from postabsorptive to postprandial conditions via the ingestion of 26.2g milk protein (MILK;  $n=9$ ) or 31.5g mycoprotein (MYCO;  $n=9$ ), where a single bout of unilateral leg extension exercise was also performed. Data were analysed with a repeated measures two-way ANOVA, with Sidak's post hoc tests applied to locate individual differences ( $P \leq 0.05$ ). Values are means, with their standard errors represented by vertical bars. Treatment  $\times$  time interaction effect; A,  $P=0.2659$ ; B,  $P=0.0003$ ; C,  $P < 0.0001$ .

**Figure 6.** Mixed muscle protein fractional synthesis rates (FSRs; A) calculated from the plasma L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine precursor pool in the postabsorptive (fasted) and postprandial (fed) state, in rested and exercised (single bout of unilateral concentric leg extensions) muscle in healthy young men. Postprandial state represents a 4 h period following the ingestion of 26.2g milk protein (MILK; *n*=10) or 31.5g mycoprotein (MYCO; *n*=9). Data were analysed with three-way ANOVA, with Sidak post hoc tests applied to locate individual differences. The delta change in FSR in response to protein ingestion (B), representing the transition from postabsorptive to postprandial conditions in both groups is also presented. Data were analysed with two-way ANOVA, with Sidak's post hoc tests applied to locate individual differences ( $P \leq 0.05$ ). Values are means, with their standard errors represented by vertical bars. † indicates a main effect of protein ingestion. There was a trend for a difference in postprandial muscle protein synthesis rates between protein conditions ( $P=0.093$ ). # represents a main effect of condition.

**Figure 7.** Skeletal muscle mechanistic target of rapamycin (mTOR) phosphorylation status, presented as a ratio of phosphorylated (p) to total protein, in the postabsorptive and postprandial state, in rested and exercised legs, after the ingestion of 26.2g milk protein (MILK; *n*=7) or 31.5g mycoprotein (MYCO; *n*=8), in young men. Values are means, with their standard errors represented by vertical bars. Data were analysed with two-way ANOVA. No significant effects were detected.

**Figure 8.** Skeletal muscle mRNA expression of genes involved in muscle protein synthesis, muscle protein breakdown, and amino acid transport in the postabsorptive and postprandial state, in rested and exercised legs, after the ingestion of 26.2g milk protein (MILK; *n*=10) or

31.5g mycoprotein (MYCO;  $n=10$ ), in young men. Data were analysed using three-way ANOVA, with Sidak's post hoc tests used to detect differences ( $P \leq 0.05$ ). Values are means, with their standard errors represented by vertical bars. There was a main effect of protein ingestion for IRS1, TSC1, TSC2, GATSL3, AKT1S1, CAPN1, FOXO3, SRF, LAT2, SNAT9, SLC38A10, DDIT4, TRIM63, and SLC38A2 ( $P < 0.05$ ). There was a time  $\times$  exercise interaction effect for MSTN, DDIT4L, FBXO32, TRIM63, SLC38A10, DDIT4, SLC38A2, TRIM32, EIF4E, LARS, TGFB1, TFEB, PIK3R1, RPS6KB1, and SLC7A1 ( $P < 0.05$ ). SMAD2 showed a main effect of exercise ( $P < 0.05$ ). RPTOR and TSC1 showed a three way interaction (time  $\times$  condition  $\times$  exercise;  $P < 0.05$ ).